John M. Wesolowski - 30 Jun 2026 Form 4 Insider Report for INTENSITY THERAPEUTICS, INC. (INTS)

Reporting relationship: Principal Accounting Officer
Issuer ticker: INTS
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2026, 16:09:24 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 20 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ John M. Wesolowski

Key filing fact

John M. Wesolowski filed Form 4 for INTENSITY THERAPEUTICS, INC. (INTS) on 01 Jul 2026.

Key facts

This page summarizes John M. Wesolowski's Form 4 filing for INTENSITY THERAPEUTICS, INC. (INTS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 16:09.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001895944 Primary reporting owner

Wesolowski John M

Relationship: Principal Accounting Officer
Address: C/O INTENSITY THERAPEUTICS, INC., 1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Signature: /s/ John M. Wesolowski
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INTS transaction

Common Stock, $0.0001 Par Value

Award

Transaction value
Shares: +3,688
Change %: +108%
Price: $3.48^*
Shares after: 7,102
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

Footnote F2

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026.

Footnote F3

On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.